Kalaris Therapeutics Inc (KLRS)

May 22, 2026

Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock By Investing.com - Investing.com Nigeria

May 22, 2026

May 22, 2026

Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock - Investing.com

May 22, 2026

May 22, 2026

Samsara entities boost control in Kalaris (KLRS) with 54.2% stake and intra-fund share deal - Stock Titan

May 22, 2026

May 22, 2026

Kalaris Therapeutics (KLRS) affiliate adds 244,300 KLRS shares - Stock Titan

May 22, 2026

May 22, 2026

Kalaris Therapeutics Inc. (KLRS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Disciplined SpendingSmart Trader Community - Newser

May 22, 2026

May 20, 2026

Kalaris Therapeutics (KLRS) Rallies +4.36% as Bulls Target $5.16 2026-05-20Covered Call ETF - Newser

May 20, 2026

May 15, 2026

Kalaris Therapeutics (KLRS) Falls -2.87% — Watching $4.82 Support 2026-05-15Open Signal Network - Newser

May 15, 2026

May 14, 2026

Kalaris Therapeutics (KLRS) Stock: Up +8.90%, Key Resistance at $5.52 2026-05-14MACD Signals - newser.com

May 14, 2026

May 14, 2026

Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target - Moomoo

May 14, 2026

May 14, 2026

Wedbush Initiates Kalaris Therapeutics(KLRS.US) With Buy Rating, Announces Target Price $17 - Moomoo

May 14, 2026

May 13, 2026

Citizens cuts Kalaris stock price target on manufacturing progress By Investing.com - Investing.com South Africa

May 13, 2026

May 13, 2026

Citizens cuts Kalaris stock price target on manufacturing progress - Investing.com

May 13, 2026

May 12, 2026

[10-Q] Kalaris Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

May 12, 2026

May 12, 2026

Kalaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 12, 2026

May 12, 2026

Raymond James reiterates Strong Buy on Kalaris stock amid trial progress - Investing.com Nigeria

May 12, 2026

May 12, 2026

Kalaris Therapeutics Reports Q1 2026 Financial Results and Advances TH103 Clinical Trials for Retinal Diseases - Minichart

May 12, 2026

May 12, 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates - Investing News Network

May 12, 2026

May 12, 2026

Kalaris Therapeutics posts smaller-than-expected Q1 net loss - TradingView

May 12, 2026

May 12, 2026

Kalaris Therapeutics (KLRS) posts Q1 2026 loss with $104.9M cash to fund trials into 2027 - Stock Titan

May 12, 2026

May 12, 2026

Eye drug TH103 nears dosing as Kalaris funds trials into 2027 - Stock Titan

May 12, 2026

May 12, 2026

Press Release: Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 10, 2026

KLRS: Kalaris Therapeutics Inc.Interactive Chart - Zacks Investment Research

May 10, 2026

May 08, 2026

KLRS Kalaris Therapeutics Q4 loss narrows more than expected, lifting shares 1.78% on positive sentiment.Financial Data - Newser

May 08, 2026

May 01, 2026

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update - MarketBeat

May 01, 2026

Apr 27, 2026

Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - MSN

Apr 27, 2026

Apr 27, 2026

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 27, 2026

Apr 24, 2026

Kalaris Therapeutics (NASDAQ: KLRS) outlines 2026 pay and board votes - Stock Titan

Apr 24, 2026

Apr 24, 2026

Kalaris Therapeutics (NASDAQ:KLRS) Stock Price Down 3.6%What's Next? - MarketBeat

Apr 24, 2026

Apr 24, 2026

[ARS] Kalaris Therapeutics, Inc. SEC Filing - Stock Titan

Apr 24, 2026

Apr 23, 2026

Kalaris Therapeutics (KLRS) Stock: Directional Bias Review | Q4 2025: Better Than ExpectedSocial Flow Trades - Newser

Apr 23, 2026

Apr 22, 2026

KLRS (Kalaris Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares post mild gains after earnings release.Hot Momentum Watchlist - Xã Châu Thành

Apr 22, 2026

Apr 17, 2026

This Dick's Sporting Goods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm

Apr 17, 2026

Apr 16, 2026

KLRS Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus

Apr 16, 2026

Apr 16, 2026

Morgan Stanley Initiates Kalaris Therapeutics at Overweight - marketscreener.com

Apr 16, 2026

Apr 16, 2026

Morgan Stanley Initiates Kalaris Therapeutics(KLRS.US) With Buy Rating, Announces Target Price $14 - 富途牛牛

Apr 16, 2026

Apr 16, 2026

Morgan Stanley initiated coverage on Kalaris Therapeutics with a new price target - Quantisnow

Apr 16, 2026

Apr 14, 2026

KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 14, 2026

Apr 14, 2026

[EFFECT] Kalaris Therapeutics, Inc. SEC Filing - Stock Titan

Apr 14, 2026

Apr 13, 2026

Kalaris Therapeutics (NASDAQ: KLRS) registers $100M ATM program with TD Cowen - Stock Titan

Apr 13, 2026

Apr 13, 2026

Kalaris Therapeutics (NASDAQ: KLRS) registers 5,000,000 shares for resale - Stock Titan

Apr 13, 2026

Apr 13, 2026

Death Cross: Will Kalaris Therapeutics Inc benefit from rate cuts2026 Macro Moves & Breakout Confirmation Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift - TipRanks

Apr 10, 2026

Apr 10, 2026

Kalaris Therapeutics IncMatthew Gall resigns as CFO effective April 14, 2026SEC filing - marketscreener.com

Apr 10, 2026

Apr 10, 2026

CFO exit at Kalaris Therapeutics (NASDAQ: KLRS) as Brett Hagen takes finance lead - Stock Titan

Apr 10, 2026

Apr 09, 2026

Volume Summary: Is Kalaris Therapeutics Inc attractive for institutional investors2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 03, 2026

Kalaris Therapeutics (NASDAQ: KLRS) files $350M shelf, $100M ATM - Stock Titan

Apr 03, 2026

Apr 03, 2026

Kalaris Therapeutics (NASDAQ: KLRS) registers 5.0M shares resale prospectus - Stock Titan

Apr 03, 2026

Apr 02, 2026

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 02, 2026